Metabolomics Market Trends

  • Report ID: 515
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Metabolomics Market Trends

Growth Drivers

  • Growing Acceptance of Metabolomics in Personalized Medicine – Metabolite profiling in biological matrices is a major tool to discover biomarkers and personalized medicine. The metabolomics studies are involved in the identification of several biomarkers that involve complex clinical phenotypes using diverse biological systems. This helps to create personalized medicine to improve drug efficacy and reduce toxicity. Worldwide metabolomics represents more than 95% of the workload in clinical laboratories. Associating metabolomics with genomics, proteomics, and transcriptomics will aid to understand the mechanism of disease, and the pathophysiology of the target clinical phenotype.
  • Increased Incidence of Chronic Diseases – Chronic diseases affect health and quality of life. Chronic diseases such as diabetes, cancer, and heart disease are the most common causes of death in the U.S.  As per the Centers for Disease Control, every year 90% of the nation’s USD 3.8 trillion in healthcare costs are attributed to people with chronic diseases and mental health conditions.
  • Funding from Government and Private Authorities – The Investment Possibility of the Undiagnosed Disease Network (UDN) announced the establishment of a Metabolomics core that'd enhance clinical and laboratory findings and aid the Network in the diagnosis of patients with unknown disorders. Numerous government financing initiatives have been launched for advanced metabolomics research. For instance, to promote the interpretation of data from metabolomics research, the National Institute of Health (NIH), has granted a grant for USD 1.37 million.
  • Technological Advancements in Scientific Instruments – NIST developed a set using human urine materials to help in metabolomics QC materials. The set consists of pooled samples from female and male smokers and non-smokers. The set is qualitatively characterized by liquid chromatography, high-resolution mass spectrometry, and NMR to detect percent differences and metabolite fold changes for the top 20 metabolites in each urine material. The adoption and regular utilization of these QC materials will help to bring harmonization to the metabolomics field in its application in research, diagnostic, testing laboratories, and varied bio-relevant industrial processes.
  • Growing Healthcare Infrastructure – The rising demand for new digital products to replace old analog systems in the healthcare sector. Disease diagnosis and medical imaging is increasing the demand for innovation of technologically advanced equipment and installation of diagnostic devices.

Challenges

  • High Price of Metabolomic Instruments - The cost and management of a group of analytical tools, that are either collectively quite expensive, or demand a sizeable amount of funds. Depending on the necessary triple, quadrupole, or high-resolution architecture, a modern gas chromatography coupled to mass spectrometry (GC-MS) system costs between USD 200k and USD 600k, a liquid chromatography coupled to mass spectrometry (LC-MS) system costs between USD 300k and USD 800k, and a nuclear magnetic resonance system cost more than USD 800k.
  • Need for Multiple Analytical Platforms
  • Complexity Increase in Interpreting Data

Metabolomics Market: Key Insights

Base Year

2022

Forecast Year

2023-2033

CAGR

~13%

Base Year Market Size (2022)

~ USD 2 Billion

Forecast Year Market Size (2033)

~ USD 5 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Base Year

2024

Forecast Year

2025-2037

CAGR

13.1%

Base Year Market Size (2024)

USD 2.56 billion

Forecast Year Market Size (2037)

USD 12.68 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 515
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of metabolomics is estimated at USD 2.83 billion.

The metabolomics market size was over USD 2.56 billion in 2024 and is poised to cross USD 12.68 billion by the end of 2037, witnessing more than 13.1% CAGR during the forecast period i.e., between 2025-2037. Growing acceptance of metabolomics in personalized medicine, increased incidence of chronic diseases, funding from government and private authorities will boost the market growth.

Asia Pacific is anticipated to dominate majority industry share by 2037, on the back of increasing demand for pharmaceutical and biopharmaceutical products developed in the regions of developing countries such as India and China.

The major players in the market include Thermo Fisher Scientific, Agilent Technologies, Biocrates Life Sciences AG, Bio-Rad Laboratories, Inc., Bruker, Danaher, Human Metabolome Technologies America Inc., LECO Corporation, Metabolon, Inc., Shimadzu Corporation.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample